



Please use the following customer number for all correspondence regarding this application.
23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 6600.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Application No.: 10/699,362

Group Art Unit: 1644

Filed: October 31, 2003

Examiner: Szperka, Michael E.

For: Humanized tissue factor antibodies

DECLARATION OF SØREN BERG PADKJÆR

I, Søren Berg Padkjær, hereby state:

1. I work in the Protein and Biophysics Department of Novo Nordisk A/S. In the course of my work, I frequently model polypeptides and analyze such information, for example, to identify the position of epitopes for particular antibodies on a target protein.

2. I have reviewed the disclosure of US Patent 6,703,494 (Kirchhofer et al.) (hereinafter referred to as the Kirchhofer '494 patent), particularly in respect of antibodies that inhibit formation of the tissue factor:factor VIIa complex.


3. The '494 patent discloses three antibodies that reportedly inhibit tissue factor:factor VIIa complex formation. These antibodies and their reported respective epitopes are:

7G11 – Epitope: K46, S47, K48, F50, Y51, T52

6B4 – Epitope: Y10, F76, Y94, E99, L104, E105

HTF1 – Epitope: F76, Y94, E99

4. To assess whether these epitopes are distinct from an epitope comprising the tryptophan residue at position 45 of tissue factor, I generated the following model of tissue factor including the epitopes of the three antibodies described in '494 patent in comparison to Trp45 using standard modeling techniques:




5. Given the spatial separation between, e.g., Lys46 and Trp45, I would expect that an antibody that was specific for an epitope comprising

Trp45 would be distinct from any of the epitopes for the three inhibitory antibodies disclosed in the '494 patent.

6. I hereby declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: June 29, 2006



Søren Berg Padkjær